[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Moriya et al., 1996 - Google Patents

In VivoInhibition of Hepatitis B Virus Gene Expression by Antisense Phosphorothioate Oligonucleotides

Moriya et al., 1996

Document ID
13465746442813651364
Author
Moriya K
Matsukura M
Kurokawa K
Koike K
Publication year
Publication venue
Biochemical and biophysical research communications

External Links

Snippet

While an important goal of treatment for hepatitis B is to prevent the development of hepatocellular carcinoma, there has been no effective therapy for it. Antisense oligodeoxynucleotide treatment could in principle inhibit hepatitis B virus gene expression …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/12Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations

Similar Documents

Publication Publication Date Title
Moriya et al. In VivoInhibition of Hepatitis B Virus Gene Expression by Antisense Phosphorothioate Oligonucleotides
JP4709545B2 (en) Modified small interfering RNA molecules and methods of use
Goodarzi et al. Antisense oligodeoxyribonucleotides inhibit the expression of the gene for hepatitis B virus surface antigen
EP2270162B1 (en) Conserved hbv and hcv sequences useful for gene silencing
Nie et al. Inhibiting effect of antisense oligonucleotides phosphorthioate on gene expression of TIMP-1 in rat liver fibrosis
US6107028A (en) Ribozymes for treating hepatitis C
US10982212B2 (en) Conserved HBV and HCV sequences useful for gene silencing
EP0759979A1 (en) Antisense inhibition of hepatitis c virus
DE69626393T2 (en) SPECIFIC OLIGONUCLEOTIDS FOR HEPATITIS B VIRUS
US20030119017A1 (en) Enzymatic nucleic acid treatment of diseases or conditions related to levels of IKK-gamma and PKR
JP2004532022A (en) Oligonucleotide-mediated inhibition of hepatitis B virus and hepatitis C virus replication
JP2012223202A (en) Conserved hbv and hcv sequences useful for gene silencing
WO1994024864A1 (en) Methods of preventing viral replication
Goodarzi et al. Organ distribution and stability of phosphorothioated oligodeoxyribonucleotides in mice
JP2003525037A (en) Methods and reagents for regulation and diagnosis of CD20 and NOGO gene expression
US20040127446A1 (en) Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
US20040054156A1 (en) Method and reagent for inhibiting hepatitis B viral replication
US20030171311A1 (en) Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection
US20020177568A1 (en) Enzymatic nucleic acid treatment of diseases or conditions related to levels of NF-kappa B
US20030068301A1 (en) Method and reagent for inhibiting hepatitis B virus replication
Cherney et al. Expression of the Epstein-Barr virus protein LMP1 mediates tumor regression in vivo
Hsieh et al. Delta virus as a vector for the delivery of biologically-active RNAs: possibly a ribozyme specific for chronic hepatitis B virus infection
US20030140362A1 (en) In vivo models for screening inhibitors of hepatitis B virus
US20030125270A1 (en) Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection
US20030073207A1 (en) Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors